Sei Investments Co. Makes New Investment in Denali Therapeutics Inc. $DNLI

Sei Investments Co. purchased a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 52,235 shares of the company’s stock, valued at approximately $1,003,000.

A number of other large investors have also made changes to their positions in DNLI. Cetera Investment Advisers purchased a new stake in Denali Therapeutics during the first quarter worth about $212,000. PNC Financial Services Group Inc. increased its holdings in Denali Therapeutics by 8.7% in the first quarter. PNC Financial Services Group Inc. now owns 9,220 shares of the company’s stock valued at $177,000 after buying an additional 739 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Denali Therapeutics by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company’s stock valued at $51,687,000 after acquiring an additional 317,872 shares during the period. D.A. Davidson & CO. lifted its position in shares of Denali Therapeutics by 3.1% during the 1st quarter. D.A. Davidson & CO. now owns 110,235 shares of the company’s stock valued at $2,117,000 after acquiring an additional 3,302 shares during the period. Finally, Bank of New York Mellon Corp boosted its stake in shares of Denali Therapeutics by 0.8% during the 1st quarter. Bank of New York Mellon Corp now owns 768,039 shares of the company’s stock worth $14,746,000 after acquiring an additional 5,952 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DNLI. Deutsche Bank Aktiengesellschaft raised their price objective on Denali Therapeutics from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Wall Street Zen raised Denali Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Denali Therapeutics in a research report on Friday, July 17th. UBS Group raised their price target on Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Finally, Wedbush reaffirmed an “outperform” rating and set a $26.00 price target on shares of Denali Therapeutics in a research note on Monday, July 13th. Thirteen research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $35.92.

Denali Therapeutics Trading Up 2.3%

Shares of Denali Therapeutics stock opened at $25.27 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.37 and a quick ratio of 8.32. Denali Therapeutics Inc. has a 1 year low of $12.58 and a 1 year high of $27.30. The company has a market capitalization of $4.04 billion, a P/E ratio of -8.90 and a beta of 1.01. The business has a 50 day moving average price of $23.85 and a 200 day moving average price of $21.43.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The firm had revenue of $3.60 million during the quarter, compared to the consensus estimate of $2.15 million. During the same period last year, the business posted ($0.72) earnings per share. Sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.61 EPS for the current fiscal year.

About Denali Therapeutics

Denali Therapeutics is a clinical?stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine?rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti?TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.